Neoadjuvant Chemoimmunotherapy in Recurrent Glioblastoma
Condition(s):GlioblastomaLast Updated:January 26, 2023Recruiting
Include Studies Not Open or Pending
Condition(s):GlioblastomaLast Updated:January 26, 2023Recruiting
Condition(s):Breast CancerLast Updated:March 25, 2024Recruiting
Condition(s):HIV-1 InfectionLast Updated:April 24, 2023Not yet recruiting
Condition(s):Relapsed/Refractory Follicular Lymphoma; Marginal Zone Lymphoma (MZL)Last Updated:March 19, 2024Recruiting
Condition(s):SCID; Omenn’s Syndrome; Reticular Dysgenesis; Wiskott-Aldrich Syndrome; Bare Lymphocyte Syndrome; Common Variable Immunodeficiency; Chronic Granulomatous Disease; CD40 Ligand Deficiency; Hyper IgM Syndrome; X-linked Lymphoproliferative Disease; Hemophagocytic Lymphohistiocytosis; Griscelli Syndrome; Chediak-Higashi Syndrome; Langerhan’s Cell HistiocytosisLast Updated:January 26, 2024Recruiting
Condition(s):Unresectable or Metastatic Melanoma or Advanced Solid Tumors; Melanoma; Uveal Melanoma; P53 Mutation; MDM2 Gene Mutation; MPNST; Cutaneous Melanoma; Mucosal Melanoma; Malignant Peripheral Nerve Sheath TumorsLast Updated:February 1, 2024Recruiting
Condition(s):Bladder SpasmsLast Updated:August 16, 2023Recruiting
Condition(s):Human Immunodeficiency VirusLast Updated:October 24, 2023Recruiting
Condition(s):Colonic NeoplasmsLast Updated:July 21, 2022Recruiting
Condition(s):Type 1 DiabetesLast Updated:August 8, 2022Recruiting
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.